المؤلفون: Hyerim Ha, Jin Hyoung Kang, Do Yeun Kim, Seung Jin Bae, Hee Yeon Lee

المصدر: BMC Health Services Research, Vol 22, Iss 1, Pp 1-7 (2022)

مصطلحات موضوعية: Values, ASCO value framework, ESMO-MCBS, Carcinoma, renal cell, Tyrosine kinase inhibitor, Immune checkpoint inhibitor, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1472-6963Test

الوصول الحر: https://doaj.org/article/5ebb2c7cee7447a9a69e3a5b75c0ca62Test

المؤلفون: Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li Qin, Qian Jiang

المصدر: Frontiers in Pharmacology, Vol 14 (2023)

مصطلحات موضوعية: PD-1/PD-L1 inhibitors, ESMO-MCBS, ASCO-VF, value, cost, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1106961/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/d8a3a6ca157444c39574ce916e0f9642Test

المؤلفون: Jing Luo, Shunlong Ou, Hua Wei, Xiaoli Qin, Rui Peng, Song Wang, Qian Jiang

المصدر: Frontiers in Public Health, Vol 11 (2023)

مصطلحات موضوعية: cancer drugs, clinical benefit, cost, ASCO-VF, ESMO-MCBS, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1109668/fullTest; https://doaj.org/toc/2296-2565Test

الوصول الحر: https://doaj.org/article/2a9eb72e085b4ccfbb292e6f966ba82cTest

المؤلفون: Shen Lin, Yaping Huang, Liangliang Dong, Meiyue Li, Yahong Wang, Dian Gu, Wei Wu, Dongni Nian, Shaohong Luo, Xiaoting Huang, Xiongwei Xu, Xiuhua Weng

المصدر: Frontiers in Pharmacology, Vol 14 (2023)

مصطلحات موضوعية: PD-1/PD-L1 inhibitors, malignant tumors, cost-benefit analysis, ASCO-VF framework, ESMO-MCBS framework, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1114304/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/35fb62de7a9c44488e05082054416077Test

المصدر: ESMO-MCBS Working Group and Extended Working Group 2023 , ' ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies (ESMO-MCBS:H) Version 1.0 ' , Annals of Oncology . https://doi.org/10.1016/j.annonc.2023.06.002Test

مصطلحات موضوعية: ESMO-MCBS, value frameworks, clinical benefit, clinical trials, haematological malignancies, quality of life

وصف الملف: application/pdf

العلاقة: https://research.manchester.ac.uk/en/publications/8a86d075-30d5-4462-b60b-dd9f2604d7bdTest

الإتاحة: https://doi.org/10.1016/j.annonc.2023.06.002Test
https://research.manchester.ac.uk/en/publications/8a86d075-30d5-4462-b60b-dd9f2604d7bdTest
https://pure.manchester.ac.uk/ws/files/267896740/PIIS0923753423007299.pdfTest

المصدر: ESMO-MCBS Working Group and Extended Working Group 2023 , ' Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit ' , Annals of Oncology , vol. 34 , no. 4 , pp. 431-439 . https://doi.org/10.1016/j.annonc.2022.12.004Test

مصطلحات موضوعية: ESMO-MCBS, guidelines, checklist, quality of life, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre

العلاقة: https://research.manchester.ac.uk/en/publications/d2cc1db0-85ce-48ef-8272-093017ecb818Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.004Test
https://research.manchester.ac.uk/en/publications/d2cc1db0-85ce-48ef-8272-093017ecb818Test
https://linkinghub.elsevier.com/retrieve/pii/S092375342204772XTest

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016/j.annonc.2022.12.009Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.009Test
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdfTest

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Planchard , D , Peters , S , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 358-376 . https://doi.org/10.1016/j.annonc.2022.12.013Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.013Test
https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
https://cris.maastrichtuniversity.nl/ws/files/192165470/Hendriks-2023-Non-oncogene-addicted-metastatic-non.pdfTest

المؤلفون: Oosting, S. F., Barriuso, J., Bottomley, A., Galotti, M., Gyawali, B., Kiesewetter, B., Latino, N. J., Martinelli, F., Pe, M., Pentheroudakis, G., Roitberg, F., Vachon, H., de Vries, E. G.E., Piccart, M., Cherny, N. I.

المصدر: ESMO-MCBS Working Group and Extended Working Group , Oosting , S F , Barriuso , J , Bottomley , A , Galotti , M , Gyawali , B , Kiesewetter , B , Latino , N J , Martinelli , F , Pe , M , Pentheroudakis , G , Roitberg , F , Vachon , H , de Vries , E G E , Piccart , M & Cherny , N I 2023 , ' Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit ' , Annals ....

مصطلحات موضوعية: checklist, ESMO-MCBS, guidelines, quality of life

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/4a8a7d86-247e-4f8e-a0f0-faa0ad450f37Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.004Test
https://hdl.handle.net/11370/4a8a7d86-247e-4f8e-a0f0-faa0ad450f37Test
https://research.rug.nl/en/publications/4a8a7d86-247e-4f8e-a0f0-faa0ad450f37Test
https://pure.rug.nl/ws/files/692945404/Methodological_and_reporting_standards_for_quality-of-life_data_eligible_for_European_Society_for_Medical_Oncology-Magnitude_of_Clinical_Benefit_Scale_ESMO-MCBS_credit.pdfTest

المؤلفون: Zarkavelis, G., Amylidi, A. L., Verbaanderd, C., Cherny, N. I., Metaxas, Y., de Vries, E. G.E., Zygoura, P., Amaral, T., Jordan, K., Strijbos, M., Dafni, U., Latino, N., Galotti, M., Lordick, F., Giuliani, R., Pignatti, F., Pentheroudakis, G.

المصدر: Zarkavelis , G , Amylidi , A L , Verbaanderd , C , Cherny , N I , Metaxas , Y , de Vries , E G E , Zygoura , P , Amaral , T , Jordan , K , Strijbos , M , Dafni , U , Latino , N , Galotti , M , Lordick , F , Giuliani , R , Pignatti , F & Pentheroudakis , G 2023 , ' Off-label despite high-level evidence : a clinical practice review of commonly used off-patent cancer medicines ' , ESMO Open , vol. 8 , no. ....

مصطلحات موضوعية: cancer, EMA, ESMO Clinical Practice Guidelines, ESMO-MCBS, off-label

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/ea500612-1811-4e95-9549-8f63ee607dd5Test

الإتاحة: https://doi.org/10.1016/j.esmoop.2022.100604Test
https://hdl.handle.net/11370/ea500612-1811-4e95-9549-8f63ee607dd5Test
https://research.rug.nl/en/publications/ea500612-1811-4e95-9549-8f63ee607dd5Test
https://pure.rug.nl/ws/files/646928853/Off_label_despite_high_level_evidence_a_clinical_practice_review_of_commonly_used_off_patent_cancer_medicines.pdfTest